#3347 COVID VACCINE RESPONSES DURING SIBEPRENLIMAB TREATMENT OF IGA NEPHROPATHY (IGAN): AN INTERIM ANALYSISKieran McCafferty, Yusuke Suzuki, Frank Engler et al.|Nephrology Dialysis Transplantation|2023Cited by 6
Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Sibeprenlimab in Healthy ParticipantsXiaoyan Zhang, Asher D. Schachter, Yanlin Wang et al.|Clinical Pharmacology in Drug Development|2023Cited by 5
#2547 Humoral response to COVID vaccine and infection is intact during sibeprenlimab treatment of IgAN: data from the ENVISION trialKieran McCafferty, David Oldach, Yusuke Suzuki et al.|Nephrology Dialysis Transplantation|2024Cited by 1
Subcutaneous VIS649, an APRIL-Neutralizing Antibody: Preliminary Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of VIS649-102, a Phase 1, Single Ascending Dose Study in Healthy VolunteersXiaoyan Zhang, Susan Sloan, Jill Yarbrough et al.|Journal of the American Society of Nephrology|2021Cited by 0